Hepion Pharmaceuticals, Inc.
HEPA
$0.06
-$0.03-35.23%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.22% | -42.11% | -66.01% | -68.87% | -32.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.78% | -37.65% | -49.28% | -88.16% | -84.21% |
| Operating Income | 9.78% | 37.65% | 49.28% | 88.16% | 84.21% |
| Income Before Tax | -19.72% | 86.72% | 57.55% | 90.29% | 73.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.72% | 86.72% | 57.55% | 90.29% | 73.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.72% | 86.72% | 57.55% | 90.29% | 73.44% |
| EBIT | 9.78% | 37.65% | 49.28% | 88.16% | 84.21% |
| EBITDA | -- | -- | 49.93% | 88.33% | 84.30% |
| EPS Basic | 16.20% | 96.76% | 99.49% | 99.89% | 99.73% |
| Normalized Basic EPS | -36.54% | 96.76% | 99.72% | 99.88% | 99.92% |
| EPS Diluted | 16.20% | 96.76% | 99.49% | 99.89% | 99.73% |
| Normalized Diluted EPS | -36.54% | 96.76% | 99.72% | 99.88% | 99.92% |
| Average Basic Shares Outstanding | 42.95% | 309.64% | 8,282.77% | 8,546.06% | 9,665.60% |
| Average Diluted Shares Outstanding | 42.95% | 309.64% | 8,282.77% | 8,546.06% | 9,665.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |